{"id":23382,"date":"2025-05-13T19:43:58","date_gmt":"2025-05-13T12:43:58","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=23382"},"modified":"2025-05-13T19:43:58","modified_gmt":"2025-05-13T12:43:58","slug":"intron-seeks-a-strategic-partner-to-explore-the-promising-market-for-mrsa-decolonization","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=23382","title":{"rendered":"iNtRON Seeks a Strategic Partner to Explore the Promising Market for MRSA Decolonization"},"content":{"rendered":"<ul type=\"disc\">\n<li><b>Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections <\/b><\/li>\n<li><b>Demonstrated its Efficacy and Safety through previous Clinical Trials <\/b><\/li>\n<li><b>Company seeks global partners to co-develop toward Commercialization<\/b><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span> and <span class=\"xn-location\">BOSTON<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">May 13, 2025<\/span><\/span> \/PRNewswire\/ &#8212; iNtRON Biotechnology, Inc., a biotechnology company focused on developing innovative endolysin-based new biological drug for superbugs and unmet medical needs, today announced the strategic initiative aimed at expanding the clinical applications of SAL200 and seeking a strategic partnership to target the prevention of surgical site infections (SSIs) by nasal MRSA decolonization.<\/p>\n<p>Methicillin-resistant Staphylococcus aureus (MRSA) remains one of the most dangerous superbugs worldwide, with rising infection rates in both hospital and community settings. Even in sterile operating environments, MRSA-related SSIs frequently originate from the patient&#8217;s own nasal or skin, potentially leading to extended hospital stays, increased treatment costs, and in severe cases, serious systemic infections such as sepsis, osteomyelitis, or endocarditis.<\/p>\n<p>High-risk surgical patients including those undergoing implant or cardiac surgeries, or those with compromised immune systems face significantly elevated risks of MRSA infections. Although mupirocin-based nasal ointments have been used as a standard of care product for the prevention of SSI, resistance rates are continuously increasing, leaving clinicians with few effective solution.<\/p>\n<p>As an intravenous injection drug for infective endocarditis and bacteremia, SAL200 has already demonstrated a strong safety profile through Phase 1a\/<span class=\"xn-money\">1b<\/span> and Phase 2a clinical trials. Encouraged by recent feedback from key clinical experts, iNtRON is now pursuing an additional indication for SAL200 as a pre-operative MRSA nasal decolonization solution.<\/p>\n<p>According to recent industry reports, the global nasal decolonization market which is closely related to SSI prevention was valued at <span class=\"xn-money\">USD 1.6 billion<\/span> in 2024 and is projected to grow at a CAGR of 7.5%, driven by heightened hospital infection control regulations and growing concern over antimicrobial resistance.<\/p>\n<p>With the strategic expansion of the clinical application of SAL200 for the promising market opportunity, iNtRON is seeking global partners to co-develop a new formulation, delivery route, and product type as a nasal or topical use, and to collaborate on preclinical and clinical studies aimed at commercialization.<\/p>\n<p>&#8220;As SAL200 has demonstrated its strong efficacy and safety as an I.V. injection formulation in the previous clinical studies, we believe it can be developed into a nasal or topical use formulation through a much simplified clinical trial process&#8221; said YOON Kyung Won, CEO. &#8220;We believe SAL200 can fill a critical gap in MRSA nasal decolonization, an area in urgent need of a new solution. We aim to begin clinical development for this new indication in 2025 and are confident that our novel solution will significantly advance efforts to prevent MRSA-related SSIs. We are open to all types of partnerships including co-development and licensing, and welcome discussion with those who share our <span>vision<\/span><span>.<\/span>&#8220;<\/p>\n<p><b>About iNtRON Biotechnology, Inc.<\/b><\/p>\n<p>iNtRON Biotechnology (<a href=\"http:\/\/www.intodeworld.com\/\" rel=\"nofollow\">www.iNtODEWORLD.com<\/a>) is a clinical-stage biopharmaceutical company at the forefront of bacteriophage-derived technology and immune therapeutics. The company specializes in developing first-in-class and first-in-concept bio-drugs to combat infectious diseases and immune-related disorders. Since its foundation and subsequent IPO on KOSDAQ, iNtRON has focused on global R&amp;BD collaborations and is committed to delivering innovative therapies that address urgent medical needs in infectious disease and immunotherapy.<\/p>\n<p><b>Contact Us<\/b><\/p>\n<p>YOON, <span class=\"xn-person\">Kyung Won<\/span> (Kevin) \/ CEO, Vice President \/ <a href=\"mailto:kwyoon@intron.co.kr\" target=\"_blank\" rel=\"nofollow\">kwyoon@intron.co.kr<\/a><br \/>SHIN, <span class=\"xn-person\">Tae Kyu<\/span> (TK) \/ BD Team Leader \/ <a href=\"mailto:tkshin@intron.co.kr\" target=\"_blank\" rel=\"nofollow\">tkshin@intron.co.kr<\/a><br \/><a href=\"http:\/\/www.intodeworld.com\/\" target=\"_blank\" rel=\"nofollow\">www.intodeworld.com<\/a><\/p>\n<p>it is iNtRON.<\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<ul type=\"disc\">\n<li><b>Aiming to Provide a Novel Solution Against Post-Operative MRSA Infections <\/b><\/li>\n<li><b>Demonstrated its Efficacy and Safety through previous Clinical Trials <\/b><\/li>\n<li><b>Company seeks global partners to co-develop toward Commercialization<\/b><\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span> and <span class=\"xn-location\">BOSTON<\/span><\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">May 13, 2025<\/span><\/span> \/PRNewswire\/ &#8212; iNtRON Biotechnology, Inc., a biotechnology company focused on developing innovative endolysin-based new biological drug for superbugs and unmet medical needs, today announced the strategic initiative aimed at expanding the clinical applications of SAL200 and seeking a strategic partnership to target the prevention of surgical site infections (SSIs) by nasal MRSA decolonization.<\/p>\n<p>Methicillin-resistant Staphylococcus aureus (MRSA) remains one of the most dangerous superbugs worldwide, with rising infection rates in both hospital and community settings. Even in sterile operating environments, MRSA-related SSIs frequently originate from the patient&#8217;s own nasal or skin, potentially leading to extended hospital stays, increased treatment costs, and in severe cases, serious systemic infections such as sepsis, osteomyelitis, or endocarditis.<\/p>\n<p>High-risk surgical patients including those undergoing implant or cardiac surgeries, or those with compromised immune systems face significantly elevated risks of MRSA infections. Although mupirocin-based nasal ointments have been used as a standard of care product for the prevention of SSI, resistance rates are continuously increasing, leaving clinicians with few effective solution.<\/p>\n<p>As an intravenous injection drug for infective endocarditis and bacteremia, SAL200 has already demonstrated a strong safety profile through Phase 1a\/<span class=\"xn-money\">1b<\/span> and Phase 2a clinical trials. Encouraged by recent feedback from key clinical experts, iNtRON is now pursuing an additional indication for SAL200 as a pre-operative MRSA nasal decolonization solution.<\/p>\n<p>According to recent industry reports, the global nasal decolonization market which is closely related to SSI prevention was valued at <span class=\"xn-money\">USD 1.6 billion<\/span> in 2024 and is projected to grow at a CAGR of 7.5%, driven by heightened hospital infection control regulations and growing concern over antimicrobial resistance.<\/p>\n<p>With the strategic expansion of the clinical application of SAL200 for the promising market opportunity, iNtRON is seeking global partners to co-develop a new formulation, delivery route, and product type as a nasal or topical use, and to collaborate on preclinical and clinical studies aimed at commercialization.<\/p>\n<p>&#8220;As SAL200 has demonstrated its strong efficacy and safety as an I.V. injection formulation in the previous clinical studies, we believe it can be developed into a nasal or topical use formulation through a much simplified clinical trial process&#8221; said YOON Kyung Won, CEO. &#8220;We believe SAL200 can fill a critical gap in MRSA nasal decolonization, an area in urgent need of a new solution. We aim to begin clinical development for this new indication in 2025 and are confident that our novel solution will significantly advance efforts to prevent MRSA-related SSIs. We are open to all types of partnerships including co-development and licensing, and welcome discussion with those who share our <span>vision<\/span><span>.<\/span>&#8220;<\/p>\n<p><b>About iNtRON Biotechnology, Inc.<\/b><\/p>\n<p>iNtRON Biotechnology (<a href=\"http:\/\/www.intodeworld.com\/\" rel=\"nofollow\">www.iNtODEWORLD.com<\/a>) is a clinical-stage biopharmaceutical company at the forefront of bacteriophage-derived technology and immune therapeutics. The company specializes in developing first-in-class and first-in-concept bio-drugs to combat infectious diseases and immune-related disorders. Since its foundation and subsequent IPO on KOSDAQ, iNtRON has focused on global R&amp;BD collaborations and is committed to delivering innovative therapies that address urgent medical needs in infectious disease and immunotherapy.<\/p>\n<p><b>Contact Us<\/b><\/p>\n<p>YOON, <span class=\"xn-person\">Kyung Won<\/span> (Kevin) \/ CEO, Vice President \/ <a href=\"mailto:kwyoon@intron.co.kr\" target=\"_blank\" rel=\"nofollow\">kwyoon@intron.co.kr<\/a><br \/>SHIN, <span class=\"xn-person\">Tae Kyu<\/span> (TK) \/ BD Team Leader \/ <a href=\"mailto:tkshin@intron.co.kr\" target=\"_blank\" rel=\"nofollow\">tkshin@intron.co.kr<\/a><br \/><a href=\"http:\/\/www.intodeworld.com\/\" target=\"_blank\" rel=\"nofollow\">www.intodeworld.com<\/a><\/p>\n<p>it is iNtRON.<\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-23382","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23382","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23382"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23382\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23382"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23382"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23382"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}